NEC
9.3.2020 04:02:12 CET | Business Wire | Press release
NEC Corporation (TOKYO: 6701) today announced a collaboration with Siemens in the IoT field to provide a monitoring and analysis solution for manufacturing that connects MindSphere®, the cloud-based, open Internet of Things (IoT) operating system from Siemens, and NEC's System Invariant Analysis Technology (SIAT). As part of the agreement, NEC is joining the MindSphere Partner Program, which can provide NEC with access to specialized technical training and support from Siemens as well as a number of joint go-to-market capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200308005027/en/
In recent years, with the acceleration of digitization and the spread of IoT, the safety, efficiency, maintenance and product quality of systems are being visualized and analyzed based on data collected from a large number of sensors installed in various locations, such as plant systems, manufacturing lines and factories. However, it is necessary to systemize data collection, storage, monitoring, analysis and other processes in order to utilize sensor data. Moreover, unique know-how, such as knowledge about IoT systems and data analysis, is required to construct such a system, making it difficult for customers to construct by themselves.
In addition, especially in the manufacturing industry, work processes are often based on the expertise of each plant or individual. Therefore, the loss of know-how due to the retirement of skilled personnel and lack of staff poses a serious challenge.
In order to solve these issues, NEC and Siemens have enhanced their products to enable greater visualization and analysis of sensor data.
System Invariant Analysis Technology, part of NEC's cutting-edge portfolio of AI technologies, "NEC the WISE", is being used to automatically learn and model the behavior of systems based on data gathered from a large number of sensors installed in large-scale, complex systems. This provides visualization of systems and how they operate, in addition to enabling systems to operate safely and efficiently by proactively detecting errors using analytical models. NEC has already installed approximately 100 such systems internationally.
MindSphere is the cloud-based, open IoT operating system from Siemens that connects products, plants, systems, and machines, enabling companies to harness the wealth of data generated by the IoT with advanced analytics. The MindSphere Partner Program is Siemens’ partner program for industrial IoT solution and technology providers.
This collaboration enables both companies to provide total data collection, storage, monitoring and analysis, including customization according to customer needs. Specifically, MindSphere is being used to collect and accumulate field sensor data and NEC's System Invariant Analysis Technology system automatically monitors and analyzes the data. This solution will first be offered as a cloud solution for the manufacturing industry, then applied to factory systems, manufacturing lines, plant facilities and other equipment, as well as products that are produced using this equipment. This makes it easy to visualize and analyze vast amounts of sensor data, thereby contributing to increased productivity, reduced operational risk, product quality and the preservation of know-how.
The companies plan to target customers in manufacturing industries internationally, then expand to customers in other industries.
"It is an honor to collaborate with Siemens to enhance the productivity of the manufacturing industry through System Invariant Analysis Technology,” said Osamu Fujikawa, Senior Vice President, NEC Corporation. “NEC will accelerate the digitization of enterprises through the provision of solutions worldwide that leverage both companies’ strengths. NEC will continue to address diversifying needs by fusing real and digital technologies as well as by leveraging advanced technologies such as AI and IoT,” he added.
"Siemens is committed to creating partnerships that help customers realize digital transformation with Industrial IoT. Working with NEC can help provide MindSphere applications that improve customers’ ability to add value to their digital transformation initiatives,” said Kunihiko Horita, Japan Country Manager, Siemens Digital Industries Software.
About NEC Corporation:
For more information, visit NEC at www.nec.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200308005027/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom